Histopathology and bronchoalveolar lavage.
Although neither lung biopsy nor bronchoalveolar lavage (BAL) is recommended for routine clinical use in patients with SSc, studies employing lung biopsy material and BAL fluid (BALF) have provided insight into the pathogenesis of scleroderma-associated interstitial lung disease (SSc-ILD). Most often, SSc-ILD is classified as a non-specific interstitial pneumonia, with abundant myofibroblasts and evidence of both epithelial cell and endothelial cell injury. Recently, SSc-ILD fibroblasts have been shown to express reduced levels of the caveolin-1 protein which, in turn, may lead to activation of the signalling molecules associated with increased collagen production and overexpression of alpha-smooth muscle cell actin (alpha-SMA). BALF often contains increased numbers of inflammatory cells as well as myofibroblasts expressing alpha-SMA. Analysis of BALF suggests an imbalance between pro-fibrotic and anti-fibrotic factors, e.g. an overabundance of TGF-beta, connective tissue growth factor (CTGF), PDGF, leucotriene B4, etc. and in some cases a deficiency of hepatocyte growth factor, 15-hydroxyeicosatetraenoic acid (15-HETE), lipoxin A, etc. Until the pathogenesis is fully understood, lung biopsy and BAL will remain useful research tools to better understand the inflammatory and fibrosing processes that underlie SSc-ILD.
Silver
R M
RM
Department of Medicine, Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC 29425, USA. silverr@musc.edu
Wells
A U
AU
D001706:Biopsy; D018893:Bronchoalveolar Lavage; D006801:Humans; D008168:Lung / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000150:complications* / Q000473:pathology; D011658:Pulmonary Fibrosis / Q000150:complications / Q000473:pathology; D012595:Scleroderma, Systemic / Q000150:complications* / Q000473:pathology; D012680:Sensitivity and Specificity
Clin Exp Rheumatol. 2004 Nov-Dec;22(6):733-42
15638048
J Biol Chem. 2001 Nov 30;276(48):45184-92
11579091
Eur J Pharmacol. 2006 Mar 8;533(1-3):222-39
16500642
Arthritis Rheum. 1984 Nov;27(11):1254-62
6497920
Am J Respir Crit Care Med. 2008 Jan 1;177(1):91-8
17901414
Proc Am Thorac Soc. 2006 Jun;3(4):377-82
16738204
Arthritis Rheum. 2003 Aug;48(8):2262-74
12905481
Am J Med. 1990 May;88(5):470-6
2337105
Am J Physiol Lung Cell Mol Physiol. 2008 May;294(5):L843-61
18203815
Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):400-6
8756813
Arthritis Rheum. 2005 Dec;52(12):3783-91
16320329
Eur Respir J. 2007 Mar;29(3):446-52
17107986
Ann Rheum Dis. 2005 Sep;64(9):1343-6
16100339
Am J Respir Cell Mol Biol. 2007 Jul;37(1):38-47
17379848
Am J Respir Cell Mol Biol. 1994 Apr;10(4):405-12
7510986
Arthritis Rheum. 2007 Jul;56(7):2432-42
17599773
J Rheumatol. 1992 Nov;19(11):1716-23
1491389
J Exp Med. 2006 Dec 25;203(13):2895-906
17178917
Arthritis Rheum. 2007 Dec;56(12):4195-202
18050251
Am J Respir Crit Care Med. 2002 Jun 15;165(12):1581-6
12070056
J Biol Chem. 2005 Apr 8;280(14):13879-87
15691837